A Remarkable Financial Year for Novo Holdings
Novo Holdings has proudly announced a record Total Income and Investment Returns of DKK 60 billion (€8.0 billion) for the year 2024. This substantial gain reflects a dramatic increase from DKK 31 billion (€4.2 billion) reported in the previous year. The driving force behind this impressive result stems from unparalleled performance in the Investment Portfolio and robust growth within the Novo Group companies, including Novo Nordisk A/S and Novonesis A/S.
Investment Portfolio Performance
The Investment Portfolio played a pivotal role, achieving remarkable returns of 18.0%, compared to 9.4% in 2023. When factoring in Special Investments, the Total Investment Return soared to 19.2%. Notably, the Income from dividends and share repurchase initiatives contributed DKK 23 billion (€3.1 billion) to the overall results, while Returns from the Investment Portfolio delivered an impressive DKK 37 billion (€4.9 billion).
Strong Growth Across Multiple Investments
Novo Holdings concluded 2024 with Total Assets under Management marked at DKK 1,060 billion (€142 billion), albeit a slight decrease from DKK 1,114 billion (€149 billion) in the previous year, primarily attributed to fluctuations in the market value of Novo Nordisk. Kasim Kutay, CEO of Novo Holdings, expressed pride in the year's achievements, highlighting the solid growth of the Novo Group companies, which have significantly contributed to the overall income and returns.
Life Science and Capital Investments
A crucial aspect of Novo Holdings encompasses its Investment Portfolio, which comprises Life Science Investments and Capital Investments. The Life Science sector represents 59% of the total portfolio, focusing on advancements that enhance human health and, increasingly, the planet's well-being. The Capital Investments team, which holds the remaining 41%, seeks to extend global exposure beyond the life sciences.
Innovation in Life Sciences
In 2024, Life Science Investments reported total Investment Assets of DKK 134 billion (€18 billion) and profits of DKK 24 billion (€3.2 billion). Noteworthy investments include allocations towards biotechnology developments aimed at creating innovative treatments for conditions such as cancer, cardiometabolic diseases, and neurodegenerative disorders. With DKK 34 billion (€4.6 billion) dedicated specifically to life sciences, the commitment to improving patient outcomes remains a top priority.
Strategic Acquisitions and Expansions
A standout moment in 2024 was Novo Holdings' landmark acquisition of Catalent, a global Contract Development and Manufacturing Organisation (CDMO) for DKK 118 billion (€16.5 billion). This significant strategic move positions Novo Holdings as a leader in the pharmaceutical services sector. Catalent, known for its robust capabilities, has played an essential role in drug development and approvals, supplying nearly 70 billion doses annually across a diverse product range.
Looking Ahead: Strategy 2030
As 2024 marked a year filled with financial successes, Novo Holdings remains committed to solidifying its operational frameworks in line with Strategy 2030. This plan involves scaling investment platforms and accelerating Planetary Health Investments aimed at ushering in a green transition across industries. As part of this ongoing evolution, Novo Holdings will establish an office in India, enhancing its focus on Asia's growing market and investment opportunities.
Frequently Asked Questions
What financial figures did Novo Holdings report for 2024?
Novo Holdings reported Total Income and Investment Returns of DKK 60 billion (€8.0 billion) in 2024.
What was the performance of the Investment Portfolio in 2024?
The Investment Portfolio achieved returns of 18.0%, with a Total Investment Return of 19.2% when including Special Investments.
Which companies are included in the Novo Group?
The Novo Group includes Novo Nordisk A/S and Novonesis A/S.
What is the focus of Novo Holdings’ investments?
Novo Holdings focuses on life sciences, including innovative health solutions and green investments for sustainable practices.
What significant acquisition did Novo Holdings make in 2024?
Novo Holdings acquired Catalent for DKK 118 billion (€16.5 billion), marking a major strategic move in the healthcare sector.
